Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Proposal To Amend MDR/IVDR May Pass ‘Final Step’ Before Adoption Next Week

Executive Summary

Amendments to support the implementation of the MDR and IVDR have appeared as provisional items on the agenda of a 7 March Council of the EU meeting, marking a potential final step before formal adoption.

You may also be interested in...



Implementing The EU MDR Amendment: “Messy” And “A Lot To Figure Out On The Hoof”

The EU Medical Device Regulation amending regulation is not some kind of “bail-out or blanket extension” for manufacturers, medtech expert lawyer Erik Vollebregt warns. But it offers valuable opportunities to already-prepared manufacturers.

EU Gives Final Thumbs Up To Altering Transition Deadlines For MDR Legacy Products

EU institutions have unanimously agreed to amendments to support the implementation of the Medical Device Regulation. The speed at which this has been done reflects the urgency of new measures to address the EU’s crisis.

EU Regulatory Roundup, May 2023: MDR Extension Updates Resume

May saw a resurgence of EU MDR news, following a few quieter weeks. Guidance on demonstrating compliance with extended transition periods and compiling clinical investigation reports were among the top-read articles in Medtech Insight in the past month.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147670

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel